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Background: Dementia patients are often cared for in institutional arrangements, which are associated with
substantial spending on professional long-term care services. Nevertheless, there is little evidence on the exact cost
differences between community-based and institutional dementia care, especially when it comes to the distinct
health care services. Adopting the perspective of the German social security system, which combines Statutory
Health Insurance and Compulsory Long-Term Care Insurance (payer perspective), our study aimed to compare
community-living and institutionalized dementia patients regarding their health care service utilization profiles and
to contrast the respective expenditures.
Methods: We analysed 2006 claims data for 2,934 institutionalized and 5,484 community-living individuals stratified
by so-called care levels, which reflect different needs for support in activities of daily living. Concordant general
linear models adjusting for clinical and demographic differences were run for each stratum separately to estimate
mean per capita utilization and expenditures in both settings. Subsequently, spending for the community-living
and the institutionalized population as a whole was compared within an extended overall model.
Results: Regarding both settings, health and long-term care expenditures rose the higher the care level. Thus,
long-term care spending was always increased in nursing homes, but health care spending was comparable.
However, the underlying service utilization profiles differed, with nursing home residents receiving more frequent
visits from medical specialists but fewer in-hospital services and anti-dementia drug prescriptions. Altogether,
institutional care required additional yearly per capita expenses of ca. €200 on health and ca. €11,200 on long-term
care.
Conclusion: Community-based dementia care is cost saving from the payer perspective due to substantially lower
long-term care expenditures. Health care spending is comparable but community-living and institutionalized
individuals present characteristic service utilization patterns. This apparently reflects the existence of setting-specific
care strategies. However, the bare economic figures do not indicate whether these different concepts affect the
quality of care provision and disregard patient preferences and caregiver-related aspects. Hence, additional research
combining primary and secondary data seems to be required to foster both, sound allocation of scarce resources
and the development of patient-centred dementia care in each setting.
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Dementia is a common syndrome in advanced age and
is characterized by a steady cognitive decline, resulting
finally in a need for long-term care [1]. The incidence of
dementia disorders increases exponentially beyond the
age of 65, and the corresponding prevalence rates ap-
proximately double for every additional five years of
age [2,3]. Around 7.2% of the German population aged
65 and older is thought to suffer from dementia –
equivalent to ca. 1.2 million patients [2]. This figure is
expected to double by 2050 as a result of demographic
change alone [4].
According to the Federal Statistical Office, the German
social security system, represented by the Statutory
Health Insurance (hereafter SHI) together with the
Compulsory Long-Term Care Insurance (hereafter
LTCI), spent ca. €10.5 billion on treating dementia disor-
ders in 2008. This equals ca. 8.4% of the entire public
health and long-term care spending on individuals aged
65 and older [5]. Dementia is a substantial economic
burden for the public health sector and, from this payer
perspective, professional long-term care in an institu-
tional setting is the crucial expense factor [6,7].
However, the exact difference in spending on long-
term care services has seldom been quantified, and there
is even less research that has analysed whether expendi-
tures on health care services also differ between institu-
tionalized and community-living dementia patients [8-11].
Within the German context, we know of only one
study that has compared expenditures directly attribut-
able to Alzheimer’s dementia in a sample of 123 institu-
tionalized and 272 community-living individuals. Based
on self-reports from a three-month recall period, yearly
per capita expenditures were estimated at ca. €4,500
(community) versus €15,300 (nursing home) for SHI and
LTCI [12]. These findings might not be generalizable as
patients were mainly recruited via memory clinics and
neurological practices. Moreover, comprehensive infor-
mation on the volume of services used is lacking. Typically,
utilization is easier to transfer to other countries and sys-
tems than cost figures [13].
To partly overcome some of these limitations, we
assessed the entire service utilization and the corre-
sponding expenditures for a large sample of community-
living and institutionalized individuals suffering from
any kind of dementia disorder via claims data from a
prominent regional SHI fund. The living environment of
the population, which might be nursing home or the
community, is further referred to as the setting.
This paper aimed to
a) Compare yearly per capita utilization and costs for
health and long-term care services between
community-living and institutionalized dementiapatients according to activities of daily living
(hereafter ADL) dependency groups (care level)
b) Investigate systematic differences regarding the
provision of distinct health care services within both
care settings.
Methods
Data source and sample selection
AOK Bavaria is the leading SHI fund in the district of
Middle Franconia covering about 50% of the population
aged 65 years and older. It provided claims data from
2005 to 2007 for all insurants born before 1941 (i.e. at
least 65 on 1 January 2006) and continuously insured
until 2007 (i.e. survivors of 2005 and 2006). Data
provision was carried out according to German data
protection laws, and AOK Bavaria approved the use of
the data set for the intended analyses. The selection
process relied on 2005 and 2006 data. Service utilization
and corresponding spending were compared for 2006.
Dementia patients were identified by means of phys-
ician diagnoses, hospital diagnoses and anti-dementia
drug prescriptions by constructing ‘dementia quarters’.
Each quarter with at least one documented dementia-
specific ICD-10 code (‘F00’, ‘F01’, ‘F02’, ‘F03’ and ‘G30’) or
with at least one filled prescription for a dementia-
specific drug (ATC codes N06DA (cholinesterase inhibi-
tors) and N06DX01 (memantine)) was defined as a de-
mentia quarter. To avoid false-positive classification as a
dementia patient, we only considered individuals with a
minimum of three dementia quarters out of four con-
secutive quarters [14,15]. At least one of these dementia
quarters was required to be documented in 2006. Using
this approach, we identified 9,147 dementia patients. A
detailed description of the selection process is described
elsewhere [16].
This sample was classified as community-living or
institutionalized in a nursing home based on a distinct
component of long-term care insurance called ‘institu-
tional care’. We decided that the starting date of pay-
ments for ‘institutional care’ would be synonymous
with transfer to a nursing home. Moreover, we
assumed institutional care only to be affordable with
LTCI support [12]. Thus, all individuals without LTCI
support were allocated to the community setting. In
one special case, an institutionalized individual with
LTCI support in 2005 received no extension of the
long-term care entitlement in 2006. We dropped this
insurant. In this way, we identified 5,584 insurants
living in the community setting and 2,934 insurants
living in an institutional setting throughout 2006. In
addition, 682 individuals were found to have trans-
ferred to a nursing home during the course of 2006,
and 46 received LTCI support for ‘institutional care in
homes for the handicapped’.
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community and the institutional setting. Therefore, we
excluded incidental nursing home residents in 2006 be-
cause they represented an independent third group that
could not be allocated definitively to one of the settings
of interest. We also disregarded individuals residing in
homes for the handicapped because their care needs
most probably differed from those of individuals residing
in regular nursing homes. Hence, our final sample con-
sisted of 8,418 dementia patients.
Within the German long-term care system, the need
for care is reflected by three care levels, which account
for the daily support required in ADL. Care level 1
reflects mild dependency, care level 2 moderate depend-
ency and care level 3 severe dependency.
Based on previous studies, we expected a different
degree of ADL dependency for individuals in each set-
ting [12,17,18] and regarded an unequal care level distri-
bution as a potential source of bias. For a comprehensive
comparison, we therefore further stratified both popula-
tions according to care level, using the care level assigned
on 30 June as the classification criterion.
Assessment of service utilization and expenditures
The German health and long-term care system
In Germany, health and long-term care insurance are a
legal obligation, and about 85% of the resident population
is insured within statutory funds. These are characterized
by pay-as-you-go financing and income-dependent but
risk-independent contributions [19].
There are no different funding sources for community-
living and nursing home-based individuals, but the re-
sponsibility of SHI versus LTCI is defined by the type
of service required: SHI covers acute health care needs
and temporary nursing needs (e.g. household support
after a fracture). It is designed as full coverage insur-
ance providing almost free access to a broad range of
medical services [19]. In contrast, LTCI accounts for
durable ADL impairment and has only a supportive
character. Hence, long-term care services are only
reimbursed up to a fixed ceiling amount, which
depends, first, on the type of service utilized and,
second, on the patient’s ‘care level’ (ADL dependency
group) [20].
LTCI data and SHI data are managed under one um-
brella, but the corresponding services are financed by ei-
ther LTCI contributions or SHI contributions.
SHI services
With regard to SHI, we assessed service utilization and
corresponding expenditures for hospital care, out-
patient treatment by physicians, medication, non-
physician services, medical aids, home health care and
rehabilitation. The per capita expenditures for 2006therefore equal the sum of expenditures within the dis-
tinct service categories.
Whenever a treatment only partly took place in 2006,
we calculated time of treatment within the year of obser-
vation. Then, expenditures were attributed proportion-
ally to time of resource use.
Utilization of physician services is reported on the
level of visits. Each visit is connected with multiple ser-
vices billed via a fee for service system which assigns a
specific score to each service. The corresponding coun-
ter value of services is calculated by multiplying this
score by a point value variable by quarter and the physi-
cian’s area of specialization.
Medication use refers to the number of prescribed
drugs. The respective pharmacy retail prices are available
from the Scientific Institute of the AOK. As well as
medication use and expenditures in general, we assessed
prescriptions and spending for dementia-specific drugs
in particular.
Hospitals provide inpatient treatment, emergency care
and certain outpatient services, all accounted for within
the category of hospital treatment. Service utilization is
described as the sum of days with any kind of hospital
treatment. Spending on hospital services is documented
directly in the claims data.
Expenditures on non-physician services and home
health care refer to prescriptions. A prescription for
non-physician services covers a fixed number of treat-
ment sessions, whereas home health care is limited to a
distinct time horizon. The absolute payment amount per
prescription depends, first, on the number of contacts
between patient and provider and, second, on the type
of services provided. These details are not traceable; in-
stead, only the total sum accrued for the delivered ser-
vices is reported. Therefore, the number of prescriptions
gives only a vague idea of effective resource utilization.
LTCI services
For nursing home residents, the LTCI offers ‘permanent
institutional care’, which includes basic and medical
nursing and social care but does not account for board
and lodging. Community-living individuals can choose
between ‘professional ambulatory nursing care’, ‘allow-
ance for nursing care’, which represents a transfer pay-
ment to informal caregivers, or a combination of both
services. Additionally, they receive short-term institu-
tional nursing care, day or night care and replacement
caregiving, if required.
However, not every insurant automatically has an en-
titlement to LTCI support. In order to benefit from LTCI
payments, individuals with ADL impairment have to file
an application to their SHI. Then, their need for care is
appraised by the Medical Review Board – an independ-
ent statutory corporation performing advisory functions
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ministry of social affairs - according to a standardized
procedure. This assessment basically accounts for ADL
needs but does not explicitly address dependency due to
cognitive impairment [21].
The Code of Social Law defines the following care
levels. Care level 1 (mild dependency) requires a mini-
mum of 90 minutes support per day, of which at least
45 minutes is dedicated to basic care. Care level 2
(moderate dependency) requires a minimum of 180 min-
utes support per day, of which at least 120 minutes is
dedicated to basic care. Care level 3 (severe dependency)
requires a minimum of 300 minutes support per day, of
which at least 240 minutes is dedicated to basic care.
At the end of the process, either the applicant is
assigned to one of these care levels or the application is
rejected. In the latter case, all long-term care services
have to be financed out-of-pocket. Otherwise, the appli-
cants receive a set amount of monthly support, which
increases the higher the care level.
As these tariffs are fixed, claims data only provide in-
formation on the utilization of a certain LTCI service
per se, but not on the intensity of service utilization.
Statistical analysis
To compare care level-specific utilization patterns and in-
surance expenditures of institutionalized and community-
living dementia patients, we applied a separate generalized
linear model (hereafter GLM) for each care level. As
individuals without care level assignment were only
observed in the community setting, we constructed
particular models for this subpopulation only. In all
these models, the influence of setting was investigated
adjusting for age, gender, the interactions ‘age*gender’,
‘age*setting’ and ‘gender*setting’ as well as for proxim-
ity to death and comorbidity.
Proximity to death was reflected by a dummy variable
which reported whether an individual survived the year
2007 or not. Comorbidity was assessed by the Charlson
Comorbidity Index [22]. To indicate the comorbidity
burden at the beginning of 2006, we accounted for all
inpatient and outpatient diagnoses documented in the
second half of 2005.
The inclusion in the models of interactions with set-
ting complicated a straightforward interpretation of the
setting effect. Therefore, we also performed simple
GLMs without interaction terms. Here, the p-value of
setting can be interpreted directly. These estimates dif-
fered only marginally from those of the full models and,
given this high accordance, we considered a significant
difference in the simple model to be transferable to the
extended model.
Age, gender and comorbidity burden differed to some
extent between the different strata. To enable acomparison across the different strata, we adjusted the
strata-specific figures on the average age, gender and
comorbidity profile across the entire study population.
This implied a mean age of 81.6 years, a female quota of
74.6% and a mean Charlson Index of 4.0 for all analyses.
We analysed the average volume of service use at the
per capita level for each category assuming a negative bi-
nomial distribution with log link.
Expenditures were estimated based on two different
approaches depending on the service category con-
cerned. Approach 1, a one-step gamma model with log
link, was applied for services used by almost every pa-
tient. These were general practitioner, medication, SHI
expenditures, LTCI expenditures and expenditures for
the social security system. To avoid excluding the few
patients without expenditures from the analyses, we
assigned them a small positive amount (€10 per person).
For the categories medical specialist, hospital treat-
ment, non-physician services, medical aids, home health
care, rehabilitation and the distinct long-term care ser-
vices, we followed approach 2. Here, we calculated two-
part regression models [23], which first assess the prob-
ability of positive expenditures via logistic regression
(part 1) and subsequently estimate the amount expended
for the individuals with positive spending by a gamma
model with log link (part 2). To derive per capita expen-
ditures, we multiplied the estimated probabilities for
positive expenditures from part 1 by the predicted
expenditures per user from part 2. Group differences
combined for both parts of the model were evaluated
using recycled predictions based on setting as the coeffi-
cient of interest [24].
Owing to the stepwise calculation, approach 2 pro-
vides two p-values, the first referring to differences in
the probability of service use (part 1), and the second
referring to expenditure differences among service
users (part 2). We defined the effect of setting as statis-
tically significant if both estimates pointed in the same
direction and if at least one of these p-values was
significant.
Another effect of the stepwise approach was a slight
difference between SHI expenditures and expenditures
for the social security system derived from the one-part
model and the sum of mean expenditures in the asso-
ciated expenditure categories.
Supplementary to the care level-stratified analyses, we
constructed an overall GLM that considers the whole
study population. In addition to the covariates described
previously, this overall model accounted for the covari-
ates care level, ‘care level*gender’, ‘care level*age’ and ‘care
level*setting’. LTCI expenditures were also estimated
within a two-part model. Apart from these modifica-
tions, the analyses followed the approaches described
above.
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which were performed with the software package SAS,
version 9.2.Results
Patient characteristics
Table 1 describes the patient population according to
care level assignment on 30 June, which reflects ADL
impairment. We found a higher level of physical inde-
pendence in the community setting. Some 3,325
community-living individuals but only one institutiona-
lized individual were not assigned to any care level. Also,
the quota of patients assigned to care levels 2 or 3 was
substantially higher in nursing homes. Across all care
levels, nursing home residents were around two yearsTable 1 Baseline characteristics
Institution Community Entire sample
Entire population
N 2,934 5,484 8,418
Age 84.3 (7.3) 80.1 (7.1) 81.6 (7.5)
Charlson Index 3.9 (2.2) 4.1 (2.4) 4.0 (2.3)
Females (as a %) 2,453 (83.6) 3,827 (69.9) 6,280 (74.6)
Death in 2007 (as a %) 747 (25.5) 719 (13.1) 1,466 (17.4)
No care level
N 1* 3,325 3,326
Age 78.8 (6.6) 78.8 (6.65)
Charlson Index 4.0 (2.4) 4.0 (2.4)
Females (as a %) 2,303 (69.3) 2,304 (69.3)
Death in 2007 (as a %) 257 (7.7) 257 (7.7)
Care level 1
N 705 1,059 1,764
Age 83.4 (7.2) 81.8 (7.0) 82.4 (7.1)
Charlson Index 3.9 (2.2) 4.1 (2.4) 4.0 (2.3)
Females (as a %) 561 (79.6) 762 (72.0) 1,323 (75.0)
Death in 2007 (as a %) 141 (20.0) 153 (14.4) 294 (16.7)
Care level 2
N 1,201 729 1,930
Age 84.1 (7.4) 82.3 (7.3) 83.5 (7.1)
Charlson Index 3.9 (2.3) 4.4 (2.4) 3.8 (2.2)
Females (as a %) 991 (82.5) 502 (68.9) 1,493 (77.4)
Death in 2007 (as a %) 293 (24.4) 180 (24.7) 473 (24.5)
Care level 3
N 1,028 371 1,399
Age 85.3 (7.3) 83.0 (7.7) 84.7 (7.5)
Charlson Index 3.7 (2.2) 4.1 (2.4) 3.7 (2.3)
Females (as a %) 900 (87.6) 260 (70.1) 1,160 (82.9)
Death in 2007 (as a %) 313 (30.5) 129 (34.8) 442 (31.6)
Data are mean (standard deviation) unless noted otherwise.
* Individual excluded from further analyses.older than community-living individuals and the share
of females was increased.
The comorbidity burden according to the Charlson
Index was slightly higher in the community but, in both
settings, the index score altered little between the care
level strata. Irrespective of care setting, the probability of
dying during the year following the observation
increased with rising ADL impairment.
Care level-based comparison of service utilization
The user quotas in Table 2 show that almost every de-
mentia patient visited general practitioners and took
medication. Other SHI services commonly used were
treatment by medical specialists and prescriptions for
medical aids. In contrast, non-physician services and es-
pecially rehabilitation were only relevant for a minority.
Comparing the percentage of community-living and
institutionalized users for the three distinct care level
strata reveals that the quota of nursing home-based
users was higher regarding medical specialists and medical
aids and, except for care level 3, regarding non-physician
services, too. The percentage of community-living service
users was higher for each care level regarding rehabilita-
tion and dementia-specific drugs.
Table 3 focuses on the intensity of per capita service
utilization and shows that nursing home residents
assigned to care levels 1 or 2 used general practitioners,
medical specialists, non-physician services, medical aids
and drugs more frequently than their community-living
counterparts, who on the other hand required anti-
dementia drugs, hospital treatment and rehabilitation on
a larger scale. In care level 3, the utilization of hospital
treatment, anti-dementia drugs and non-physician ser-
vices was comparable in both settings. Similar to care
levels 1 and 2, physician visits and medical aid prescrip-
tions were higher in nursing homes but, in contrast to
the lower care levels, drug intake was increased in the
community.
Development of utilization profiles across care levels
As outlined in Table 3, the per capita demand of
community-living dementia patients for general practi-
tioners, drugs, non-physician services and medical aids
increased steadily with rising ADL dependency but, in
parallel, the use of medical specialists decreased. The
number hospital days and dementia-specific drug pre-
scriptions also declined continuously from care level 1
to care level 3, but here individuals with no care level
entitlement had lower volumes of service use than those
assigned to a care level.
In the institutional setting, we observed a linear in-
crease in prescriptions for medical aids from care level 1
to care level 3 and a linear decrease in prescriptions for
dementia-specific drugs. Within all other SHI services,
Table 2 User quota of health care services in 2006 according to care levels




Care level 1 Care level 2 Care level 3





value(n=3,325) (n=705) (n=1,059) (n=1,201) (n=729) (n=1,028) (n=371)
General practitioner (v) 99.1% 100.0% 99.5% ns 100.0% 100.0% ns 100.0% 99.5% ns
Medical specialist (v) 85.5% 86.6% 79.3% ** 87.1% 72.9% *** 77.8% 61.6% ***
Medication (p) 99.1% 100.0% 99.9% ns 100.0% 100.0% ns 99.7% 100.0% ns
of which anti-dementia drugs
(p)
16.5% 10.2% 21.2% *** 9.5% 15.4% *** 5.0% 8.5% *
Hospital treatment (d) 35.1% 40.0% 43.2% ns 46.3% 45.5% ns 39.7% 41.3% ns
Non-physician services (p) 17.8% 25.9% 22.1% * 38.3% 29.7% ** 31.6% 33.3% ns
Medical aids (p) 42.0% 84.8% 54.0% *** 94.6% 59.8% *** 96.9% 70.9% ***
Rehabilitation 5.4% 1.4% 7.2% *** 0.9% 3.6% ** estimation not possible ./.








* p≤0.05; ** p ≤0.001, *** p≤0.0001; ns=not significant.
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ume of per capita utilization than those in care levels 1
and 3.
Service expenditures
Compared with the community setting LTCI spending
was remarkably increased in nursing homes, as shown in
Table 4. The additional expenses amounted to ca. €8,900
in care level 1, ca. €7,700 in care level 2 and ca. €5,800
in care level 3. In contrast, SHI spending was higher in
the community by ca. €1,100, ca. €200 and ca. €1,100
respectively.Table 3 Per capita health care service utilization in 2006 acco





Community Institution Community p
va(n=3,325) (n=705) (n=1,059)
General practitioner (v) 28.9 52.4 33.2 *
Medical specialist (v) 10.8 12.6 8.7 *
Medication (p) 25.1 36.5 32.5 *
of which anti-dementia drugs
(p)
0.7 0.5 1.0 *
Hospital treatment (d) 5.8 6.3 8.4
Non-physician services (p) 0.5 1.2 0.9
Medical aids (p) 0.8 3.3 1.2 *
Rehabilitation (d) 1.3 0.1 1.8 *




* p≤0.05; ** p ≤0.001, *** p≤0.0001; ns=not significant.These overall SHI expenses also account for ‘home
health care’, which is by definition not offered to institu-
tionalized individuals. If only services available to both
patient populations were looked at, the difference in
expenditures basically evened out.
A detailed look at the distinct SHI services revealed
that expenditures on dementia-specific medication, hos-
pital treatment and rehabilitation were higher within all
care levels in community-living individuals and expendi-
tures on general practitioners and medical specialists
were higher in institutionalized individuals. Regarding non-
physician services, medical aids and overall medication, therding to care levels
a according to care level adjusted for age, gender, comorbidity,
le interactions






value(n=1,201) (n=729) (n=1,028) (n=371)
** 55.0 35.8 *** 54.5 40.8 ***
** 15.0 7.2 *** 12.3 6.4 ***
** 42.1 37.9 ** 38.4 46.8 ***
* 0.4 0.8 * 0.2 0.5 ns
* 7.6 8.3 ns 6.4 7.0 ns
* 2.0 1.5 * 1.8 2.0 ns
** 5.0 1.6 *** 6.3 3.6 ***






Table 4 Per capita expenditures on health and long-term care according to care level
Setting-specific expenditures (€) on health care and long-term care services per capita according to care level adjusted for age, gender,
comorbidity, mortality and single interactions
No care
level
Care level 1 Care level 2 Care level 3





value(n=3,325) (n=705) (n=1,059) (n=1,201) (n=729) (n=1,028) (n=371)
Health insurance* 4,018 4,666 5,830 s 6,162 6,395 ns 5,962 7,139 s
without home health care* 3,593 4,681 4,888 ns 6,159 5,425 s 5,965 6,449 ns
General practitioner 515 777 634 s 771 701 s 746 805 s
Medical specialist 380 366 350 s1 387 237 s 282 194 s1
Medication 824 1,221 1,195 s 1,638 1,416 s 1,762 2,251 s
of which anti-dementia
drugs
125 81 177 s1 15 118 s2 29 90 s
Hospital treatment 1,573 1,751 2,199 s2 2,333 2,425 ns 1,908 2,037 ns
Non-physician services 50 182 127 s 329 281 s2 301 452 s2
Medical aids 85 391 150 s 676 201 s 932 632 s
Rehabilitation 180 28 246 s2 29 128 s2 estimation not possible ./.







Long-term care insurance 0 12,068 3,173 s 14,850 7,168 s 16,714 10,929 s









Social security system* 4,018 16,982 9,047 s 21,208 13,795 s 22,921 18,437 s
s=significant in parts 1 and 2 of the two-part model or in the one-part model; s1=significant in part 1 of the two-part model; s2=significant in part 2 of the two-
part model; ns=not significant.
* Results of model estimation; Addition of mean costs per category yields slightly different figures.
Table 5 Per capita service utilization and expenditures (€) in 2006 across all care levels






Difference Community (care level)
(n=2,159)
Difference
Volume Costs Volume Costs Costs p-value Volume Costs Costs p-value
Health insurance* 5,693 5,466 227 s 6,424 −731 s
without home health care* 5,678 4,759 919 ns 5,533 145 ns
General practitioner (v) 54.3 761 33.2 626 135 s 37.6 705 56 s
Medical specialist (v) 13.0 327 8.8 310 17 s 7.2 264 63 s
Medication (p) 38.8 1,636 33.0 1,270 366 ns 41.1 1,569 67 ns
of which anti-dementia drugs (p) 0.3 49 0.7 129 −80 s 0.6 131 −82 s
Hospital treatment (d) 6.2 1,904 7.2 1,990 −86 ns 7.5 2,253 −349 s1
Non-physician services (p) 1.7 295 1.1 189 106 s2 1.7 281 14 s2
Medical aids (p) 5.3 742 1.5 216 526 s 2.6 303 439 s
Rehabilitation (d) 0.1 16 1.1 140 −124 s2 0.7 128 −112 s2
Home health care (p) not provided 2.8 694 −694 ./. 4.1 893 −893 ./.
Long-term care insurance 15,340 4,159 11,181 s 6,810 8,530 s
of which transfers to informal care 2,082 −2,082 ./. 3,414 ./.
Social security system* 21,388 9,765 11,623 s 13,477 7,911 s
v=visits; p=prescriptions; d=days.
s=significant in parts 1 and 2 of the two-part model or in the one-part model; s1=significant in part 1 of the two-part model; s2=significant in part 2 of the two-
part model; ns=not significant.
* Results of model estimation; Addition of mean costs per category yields slightly different figures.
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curred higher spending in care levels 1 and 2 but lower
spending in care level 3.
From care level 1 to care level 3, the LTCI expendi-
tures rose by ca. €7,800 in the community and by ca.
€4,600 in nursing homes. The corresponding additional
amount for SHI was ca. €1,300 in both settings. As a
consequence, the excess spending for institutional care
concurrently declined the higher the care level, albeit
the overall spending for both populations increased.
Comparison across all care levels
According to Table 5, only the categories medication
and hospital treatment required comparable financial
resources, if the entire population of community-living
dementia patients is compared with their institutiona-
lized counterparts. Expenditures on general practi-
tioners, medical specialists, non-physician services and
medical aids were higher in nursing homes but expendi-
tures on anti-dementia drugs and rehabilitation were
higher in the community. Altogether, the yearly per
capita spending of SHI on institutionalized dementia
patients was increased by ca. €200 and the yearly per
capita spending of LTCI by ca. €11,200.
Additionally, we performed this comparison for the
subpopulation of dementia patients with care level as-
signment. Now, the institutionalized population had
reduced SHI spending by ca. €700 and increased LTCI
spending by ca. €8,500.
Discussion
Within the German social security system, the yearly per
capita health and long-term care expenses on institutio-
nalized dementia patients amount to ca. €21,400, of
which almost three quarters is attributable to profes-
sional long-term care. The overall spending on
community-living dementia patients is ca. €9,800 – less
than half as much – and at ca. €4,200, the corresponding
long-term care expenses are substantially lower.
A comprehensive comparison of both settings accord-
ing to ADL dependency reveals a trend of rising costs of
care with greater physical impairment. Comparing
mildly dependent patients with severely dependent ones,
the increase – including, again, SHI and LTCI – is
ca. €9,400 (+104%) in the community and ca. €5,900
(+35%) in nursing homes. In both patient groups, the
long-term care expenses rise more than the health care
expenses: SHI spending on nursing home residents
increases by ca. €1,300 (+28%) but LTCI spending by
ca. €4,600 (+ca.38%). The corresponding figures for
community-living individuals are ca. €1,300 (+22%) in
SHI and ca. €7,800 (+245%) in LTCI.
A rise in expenditures from care level to care level was
by and large expected, even though it has to beconsidered as artificial regarding long-term care: LTCI
tariffs are fixed by legal definition and, hence, different
from SHI payments, partially detached from effective
needs.
Focusing on the distinct SHI categories, the utilization
of routine services increases at higher care levels, but
more complex services (medical specialist, hospital, re-
habilitation) are utilized less frequently. This might
indicate that specialized, interactive – and therefore
costly – treatment approaches that aim to restore the
patients’ capabilities for independent living are perhaps
not considered promising any longer when a certain de-
gree of ADL dependency is reached.
Comparing the health care expenditures between both
settings, it has to be kept in mind that SHI services in-
clude ‘home health care’, which accounts for short-term
medical nursing and temporary household support in
community-living individuals. These services are by def-
inition not available for nursing home residents. To
fairly judge the costs of health care service provision
within the distinct settings, we thus contrasted SHI
spending exclusive of expenditures on home health care.
In doing so, we found no significant difference between
both patient populations.
Despite the fact that overall health care expenses for
community-living and institutionalized dementia patients
are comparable, the underlying utilization patterns show
some notable differences.
First, community-living dementia patients have more
inpatient days than their institutionalized counterparts.
Our result is similar to the findings of two US-based
studies which reported more frequent hospital admis-
sions in community-living elderly patients [9,25]. This
suggests that some acute illnesses overburden informal
family caregivers but can be brought under control by
professional nursing staff in institutions, which renders
hospitalization dispensable sometimes. A further contri-
bution to extended inpatient days in community-living
dementia patients might be the relieving effect on infor-
mal family caregivers.
Obviously, community-living dementia patients face
an increased risk of inpatient treatment, and SHI should
consider offering caregiver support programmes and
case management approaches to prevent avoidable
hospitalizations.
Second, contrary to previous studies [8,12], there is no
evidence for worse access of nursing home residents to
medical specialists. The contact frequency is comparable
with most medical specialists and even significantly
increased regarding internal specialists and neurologists.
Nursing home residents might have more regular access
to specialized medical care because some medical spe-
cialists visit their institutions according to a fixed sched-
ule. Thus, it seems to be easier to get an appointment
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lized dementia patients might receive more systematic
treatment of physical comorbidity and dementia-related
symptoms.
To achieve a corresponding advantage for the
community-living population, it would be advisable to
develop recommendations on which medical specialists
have to be visited regularly. Moreover, especially in rural
areas, innovative remuneration schemes might be
required to secure a sufficiently dense network of specia-
lized care.
Third, a higher quota of community-living than of
institutionalized dementia patients receives dementia-
specific pharmacological treatment. A corresponding dif-
ference was also observed by Reese et al. [12]. Perhaps
physicians feel more obliged to tap the full potential of
pharmacological treatment in community-living indivi-
duals, whose families most likely feel overburdened by
worsening dementia symptoms, than in institutionalized
dementia patients, whose disease progression is wit-
nessed by professional nursing staff with a larger per-
sonal distance.
Although dementia-specific drugs can achieve tempor-
ary symptomatic improvement and postpone the inevit-
able disease progression, only 12.8% of our study sample
received cholinesterase inhibitors or memantine. The
minor relevance of anti-dementia drug therapy was also
stated within another recent German claims data ana-
lysis [26].
To improve adequate pharmacological treatment, phy-
sicians need to be more aware of the beneficial aspects
of anti-dementia drugs. To this end, they could be
offered targeted vocational training.
To better judge the informative value of our findings,
the strengths and weaknesses of claims data-based stud-
ies have to be considered.
First, claims data lack information on cognitive status [6].
Thus, we had no means of stratifying our analyses
according to dementia severity itself. Given sufficient
evidence that dementia progression increases the risk
of institutionalization, it must be concluded that insti-
tutionalized patients are at a more advanced disease
stage. If accepting a relation between cognitive and
physical decline [27], the care level strata can serve as a
rough proxy for disease severity and at least partially
reflect how worsening symptoms of dementia affect
health and long-term care expenditures in both
settings.
Second, the documented diagnoses cannot be verified
via medical examinations; thus, their accuracy is not ab-
solutely guaranteed [28-31]. To avoid including false-
positive cases, we required multiple dementia quarters.
To incur multiple dementia quarters, an individual
needs regular contact with the health care system. Thisimplies the selection of dementia patients, who in
principle have a higher morbidity burden than the entire
population of insurants with dementia. Hence, our esti-
mates most probably represent a ceiling amount for per
capita expenses for dementia patients within the German
social security system.
Third, claims data barely provide information on edu-
cational level, economic situation and family status, but
these factors influence the intensity of demand for pro-
fessional long-term care. We assume that the denser the
informal care network, the lower the need for profes-
sional support. The LTCI component ‘allowance for
nursing care’ allows the identification of whether infor-
mal care is available, but does not assess the informal
care hours exactly. Among the community-living indivi-
duals in our sample, ‘allowance for nursing care’
accounts for approximately 50% of LTCI spending, and
almost every insurant receives corresponding payments.
Obviously, informal care plays a crucial role for
community-living dementia patients and professional
care has a barely supplementary character. In contrast,
care provision is almost totally professional in nursing
homes. The dimensions of confounding resulting from a
different degree of professionalization remain unclear.
On the other hand, claims data-based patient samples
seem to be better suited to describing routine care than
study samples recruited from neurological wards and
memory clinics [10,12] because the patient clientele is
less selective. Moreover, claims data provide compara-
tively reliable figures because, contrary to survey-based
estimates, recall bias, cost unit definition and extrapola-
tion rules are dispensable. Third, claims data-based esti-
mates are less influenced by single outliers because of
their large sample sizes.
Despite its limitations, to our knowledge, our analysis
is one of the most comprehensive comparisons between
community-living and institutionalized dementia patients
from a payer perspective yet undertaken. It addresses
the different case mix in nursing homes and the com-
munity by care level-stratified analyses adjusting for
age, gender, morbidity and mortality to ensure the best
possible comparability between settings. Moreover, it
presents costs of care on a disaggregated level and
itemizes the distinct health care services. This allows
easy tracing of which components first and foremost
trigger SHI spending. As comprehensive care strategies
have to consider the health and long-term care needs
of dementia patients, the chosen perspective includes
both the SHI and the LTCI, although they are basically
independent insurance branches. In doing so, our study
revealed that community-based care for dementia
patients is the cost-saving option for the German social
security system because of significantly lower long-
term care expenditures.
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sented payer-based view is not necessarily in accordance
with the societal perspective. Here, production losses
and expenditures on behalf of the patients and their
families would also be accounted for. For example, food
and lodging in nursing homes have to be financed pri-
vately. In 2007, nursing home fees averaged €1,900 per
month for care level 1, €2,300 for care level 2 and
€2,800 for care level 3 [20]. Thus, only around 50% of
monthly expenditures are covered by LTCI tariffs. This
comes close to the results of a Belgian study, in which
around 55% of expenditures for institutionalized demen-
tia patients were borne by their families [8]. A fair com-
parison should thus consider food and lodging in
community-living individuals. This approach was fol-
lowed by Kuo et al. and yielded 2.5 times higher spend-
ing in the community [10].
Moreover, community-based care is associated with
substantial costs of informal care [10,12,32], which most
probably overcompensate for savings on professional
long-term care services. Altogether, the economic advan-
tage of community-based dementia care cannot be
judged unambiguously from a societal perspective.
In addition, pure financial figures abstract away from
quality of service delivery, caregiver-related issues and
patient preferences. Future research combining primary
and secondary data could account for these manifold
aspects of dementia care. This would allow a more com-
prehensive judgement on the preferability of both set-
tings and help to understand why – despite shared
clinical and demographic characteristics – some demen-
tia patients are cared for in the community and others
in nursing homes.
Conclusion
Community-living and institutionalized dementia patients
differ regarding their demographic and clinical characteris-
tics, and both settings are obviously not equivalent options
for any particular patient. Thus, efforts aiming to postpone
nursing home placement have to be scrutinized critically
even though community-based care is the cost-saving op-
tion from a payer perspective. To improve a sound alloca-
tion of scarce resources, it seems to be more advisable to
develop comprehensive care concepts for both settings. In
this regard, it has to be analysed whether the indicated
existence of setting-specific health care strategies –
represented by different service utilization profiles of
community-living and institutionalized individuals –
affects the quality of care provision. Ideally, patient pre-
ferences and caregiver-related issues should also be
integrated into a comprehensive picture on patient-
centred dementia care. This ambitious goal requires fu-
ture study approaches combining primary data on
qualitative aspects and secondary data on costs.Competing interests
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